NionyxBio

@2048vc Thank you for the shoutout!

🗞️ 2048 Ventures Portfolio Company News: Nionyx Bio's kidney gene therapy wins the 2026 BIO-Europe Spring Startup Spotlight podcast.labiotech.eu/1995493/episod… @NionyxBio // @2048vc // #startups // #VC

@NionyxBio won 1st place at the BIO-Europe Spring Startup Spotlight yesterday in Lisbon. 🏆 What a week. Incredible to be here with my Co-founder & CTO Leszek Lisowski! We’re building next-generation AAV gene therapy for the kidney. Proprietary capsids screened from human kidney tissue. Pipeline starting with Alport syndrome. Kidney-first, from day one. Onward. 🚀

Nionyx Bio won 1st place at the BIO-Europe Spring Startup Spotlight yesterday in Lisbon. 🏆 We're building next-generation AAV gene therapy for the kidney. Proprietary capsids screened from human kidney tissue. Pipeline starting with Alport syndrome. Onward!

RT @Mtyrpien: Yesterday I attended the first-ever @CNBC cures summit, hosted by @BeckyQuick and put together by her and husband, Matt Quayl…

Today is #RareDiseaseDay. There are over 150 rare kidney diseases, many genetic. At Nionyx, we're building the platform that changes that. Precision gene therapy for kidney diseases long left behind. We're in it for them. #RDD2026 #GeneTherapy #KidneyDisease #alportsyndrome

Great seeing friends and colleagues and joining the Gene Therapy 2.0 panel at #ATW2026 Learning from the past. Building what’s next! With @ForgeBio + @RayTherapeutics . #GeneTherapy #AAV @NionyxBio

We’ll be at Advanced Therapies Week in San Diego (Feb 9–12). Catch our panel: Gene Therapy’s Second Act: Scaling for Sustainable Impact Feb 10 | 2:15 PM PT @ForgeBio @RayTherapeutics #ATW26 #GeneTherapy #AAV #AdvancedTherapies

I am thrilled to share that we raised an oversubscribed $82M Fund III to lead pre-seed and seed rounds in Vertical AI, Deep Tech, Healthcare and Biotech startups in NYC and Boston. To be exact, we raised $82,048,000 - a number that felt on-brand for a nerdy firm like ours that loves riddles, the future, Morse code, and Easter eggs. We are immensely grateful to our LPs for their ongoing belief in our strategy and approach. We are equally grateful to the founders who have chosen to partner with us. Here is 2048 Ventures Ventures Fund III in a nutshell: - We back exceptional, ultra-competitive, visionary founders. - We lead pre-seed and seed rounds with $500K - $3M checks. - We invest in Vertical AI, Deep Tech, Healthcare and Biotech. - We invest primarily in NYC and Boston. - We seek businesses with strong data moats. Read more about where we’re excited to invest: 2048.vc/blog/2048-vent… If you are a builder and visionary looking for the highest conviction first-check investor, please reach out or re-share with your network!

We are thrilled to share that we raised an oversubscribed $82M Fund III to lead pre-seed and seed rounds in Vertical AI, Deep Tech, Healthcare and Biotech startups in NYC and Boston. To be exact, we raised $82,048,000 - a number that felt on-brand for a nerdy firm like ours that loves riddles, the future, Morse code, and Easter eggs. We are immensely grateful to our LPs for their ongoing belief in our strategy and approach. We are equally grateful to the founders who have chosen to partner with us. Here is @2048vc Ventures Fund III in a nutshell: - We back exceptional, ultra-competitive, visionary founders. - We lead pre-seed and seed rounds with $500K - $3M checks. - We invest in Vertical AI, Deep Tech, Healthcare and Biotech. - We invest primarily in NYC and Boston. - We seek businesses with strong data moats. Read more about where we’re excited to invest: 2048.vc/blog/2048-vent… If you are a builder and visionary looking for the highest conviction first-check investor, please reach out.

Congrats to our seed lead, @2048vc on their oversubscribed $82M Fund III!They were our first check in, led our seed, and set the tone for how we want to build: high conviction, high standards, move fast. The team is brilliant, thoughtful, and relentless in the best way. Huge congrats to @alexiskold @JulieMarieWolf and @sperezbaos We are lucky to have such a likeminded partner in our corner at @NionyxBio lets go!!! 🚀🚀🚀

What an incredible #JPM26. Sprinting across SF between meetings, catching up with peers, partners, and collaborators. The momentum behind curative, organ-specific gene therapy is real. Exciting time to be building gene therapy for the kidney. 🚀 let’s go @NionyxBio #GeneTherapy #Biotech #KidneyResearch

@LifeSciVC @AimeeRaleigh13 Couldn’t agree more on kidney. Precision targeting + gene therapy is the next frontier for GT, core to what we’re building at @NionyxBio!

First American Society of Nephrology✔️ At Nionyx, we are building next-generation kidney AAV therapies to help make a meaningful impact for patients. We are privileged and excited to be here. Onwards. #asn #kidneytherapy #genetherapy

A very productive week for our team at the European Society of Gene and Cell Therapy (ESGCT) meeting in Spain! We’re grateful for the incredible discussions with colleagues and collaborators who share our sense of urgency and alignment around accelerating progress!

We are thrilled to announce our latest investment in @NionyxBio! Read more about why we invested 👇 2048.vc/blog/our-inves… 💡 Nionyx Bio builds AAV-based gene therapies to address some of the most potent kidney genetic diseases. 👩‍💻 The Founders: @Mtyrpien & Leszek Lisowski 📌 Location: New York 💰 Investment Stage: Seed

We couldn’t be more excited to have @2048vc lead our seed round at @NionyxBio. From the very first conversations with @alexiskold, @JulieMarieWolf and @sperezbaos, we clicked — fast-paced, brilliant, thoughtful, and deeply aligned on the urgency of building a new standard in kidney gene therapy. Thrilled that @JulieMarieWolf is joining our board as we accelerate toward our next milestones. The partnership and conviction from the 2048 team means the world to us. Onwards!

I’m proud to announce the launch of @NionyxBio with our $4M seed financing, led by @2048vc with participation from Empire State Development (NY Ventures), White Mug Healthcare, AIN Ventures,and Pathway Bioventures. Together with our Co-Founder & CTO Leszek Lisowski, PhD, MBA and CMO, Head of Preclinical Development Juan Ruiz we are building the first AAV Kidney Atlas and advancing innovations in capsid, cassette, and delivery — purpose-built for precision, efficacy, and most importantly safety. In this video, I share why this is only the beginning — and how we’re working to engineer therapies that set a new standard for patients long left behind. Watch below and read the full announcement here: lnkd.in/egPm2Vrd

Monumental day at Nionyx! Coming out of stealth with $4M in seed financing, led by @2048vc with participation from Empire State Development (NY Ventures), White Mug Healthcare, AIN Ventures, and Pathway Bioventures. Read the full press release here:lnkd.in/eBiNegQr

3-for-3 working with Juan Ruiz — first at @AbeonaBio , then @ForgeBio , and now at @NionyxBio as our CMO & Head of Preclinical Development. Honored to keep building together and excited for what’s ahead!